ARTICLE | Company News
Merck sales and marketing update
September 28, 2015 7:00 AM UTC
The U.K.’s NICE issued a final appraisal determination (FAD) recommending Keytruda pembrolizumab to treat unresectable or metastatic melanoma in patients with disease progression following Yervoy ip...